All In Biotech

Drug Trial Radar · NCT07555054

A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease

A Randomized, Multicenter, Double-blind, Parallel Active-control Study of the Efficacy and Safety of HS-10390 for the Treatment of Participants With Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Nov 11, 2027

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to evaluate the efficacy and safety of HS-10390 in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 30 and \<90 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and \< 3000 mg/g

Conditions

  • Chronic Kidney Disease

Interventions

  • HS-10390Drug

    HS-10390

  • HS-10390Drug

    HS-10390

  • HS-10390Drug

    HS-10390

  • IrbesartanDrug

    Target dose of 300 mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12Time frame: Frame: From baseline (Day 1) until Week 12 (Day 85)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.